Exact Sciences Posts Flat Q1 Revenues; Loss More than Doubles as Clinical Trial Costs Spike | GenomeWeb

NEW YORK (GenomeWeb News) – Exact Sciences today reported revenues for the first quarter were flat year over year, while its net loss more than doubled.

For the period ended March 31, the Madison, Wis.-based molecular diagnostics firm brought in revenues of $1.0 million, the same as a year ago, matching Wall Street estimates. All revenues for the quarter were derived from license fees. It had no product royalty fees in the quarter compared to $4,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.